伊达比星、阿糖胞苷联合纳武利尤单抗治疗新诊断急性髓系白血病或高危骨髓增生异常综合征的单臂2期研究
这项单臂2期研究在MD Anderson癌症中心纳入44例新诊断急性髓系白血病或高危骨髓增生异常综合征患者,评估伊达比星、阿糖胞苷诱导化疗后加入纳武利尤单抗的疗效与安全性。
要点
- 纳武利尤单抗加入伊达比星和阿糖胞苷诱导方案可行,未发生归因于纳武利尤单抗的治疗相关死亡。
- 44例中19例(43%)获得缓解并接受异基因造血干细胞移植,移植后3-4级移植物抗宿主病见于5例(26%)。
- 6例患者发生7例次3-4级免疫相关不良事件,包括皮疹2例、结肠炎2例、转氨酶升高、胰腺炎和胆囊炎各1例。
核心结论
- 在新诊断急性髓系白血病或高危骨髓增生异常综合征患者中,于伊达比星和阿糖胞苷诱导化疗基础上加用纳武利尤单抗是可行的。
- 移植后严重移植物抗宿主病有待改善,未来研究有必要更早启动检查点抑制剂治疗。
研究设计与样本
- 该研究为1-2期研究中纳武利尤单抗联合伊达比星和阿糖胞苷的单臂2期部分,在德克萨斯大学MD Anderson癌症中心开展。
- 纳入年龄18-60岁(或>60岁但适合强化化疗)、新诊断急性髓系白血病或高危骨髓增生异常综合征、ECOG体能状态0-2的患者,共44例。
- 主要终点为无事件生存,次要终点为无复发生存和总生存,疗效与安全性分析纳入所有至少接受一剂研究治疗的患者。
主要发现
- 44例患者中22例(50%)按欧洲白血病网络分类为不良遗传学风险。
- 19例(43%)患者获得缓解并接受异基因造血干细胞移植,其中5例(26%)发生3-4级移植物抗宿主病。
- 6例患者发生7例次3-4级免疫相关不良事件:皮疹2例、结肠炎2例、转氨酶升高1例、胰腺炎1例、胆囊炎1例。
关键数值与推荐
- 纳武利尤单抗3 mg/kg于第24天(范围22-26)开始,每2周一次,缓解者持续至多1年。
- 缓解者接受至多5个周期的减量伊达比星和阿糖胞苷巩固化疗,或符合条件者接受异基因造血干细胞移植。
临床怎么用
- 对于适合强化化疗的新诊断急性髓系白血病或高危骨髓增生异常综合征患者,可考虑在伊达比星和阿糖胞苷诱导后加用纳武利尤单抗。
- 治疗过程中需监测免疫相关不良事件,包括皮疹、结肠炎、转氨酶升高、胰腺炎和胆囊炎。
- 接受异基因造血干细胞移植的患者需关注移植物抗宿主病,尤其是3-4级事件。
局限性
- 本研究为单臂2期研究,未设对照组,样本量44例。
- 纳武利尤单抗起始时间较晚(第24天),可能影响疗效,未来研究需探索更早启动。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Outcomes for younger patients with acute myeloid leukaemia have moderately improved over the past two decades owing to better supportive care and recent introduction of novel targeted agents. Blocking PD-1 and its ligand's pathways enhances antileukaemia responses by enabling T cells in murine models. We aimed to assess the addition of nivolumab to frontline therapy with idarubicin and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome. METHODS: This single-arm, phase 2 part of the phase 1-2 study of nivolumab in combination with idarubicin and cytarabine was done at the University of Texas MD Anderson Cancer Center (Houston, TX, USA). Eligible patients were aged 18-60 years (or >60 years if suitable for intensive chemotherapy), and had newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome, and an Eastern Cooperative Oncology Group performance status of 0-2. Induction included cytarabine 1·5 g/m2 by 24-h continuous infusion daily on days 1-4 (3 days in patients >60 years) and idarubicin 12 mg/m2 daily on days 1-3. Nivolumab 3 mg/kg was started on day 24 (range 22-26) and continued every 2 weeks for up to a year in responders. Responders received either up to five consolidation cycles of attenuated doses of idarubicin and cytarabine, or allogeneic stem cell transplantation if eligible. The primary endpoint was event-free survival. Efficacy and safety analyses were done in all patients who received at least one dose of study treatment. Secondary endpoints were relapse-free survival and overall survival. This ongoing trial is registered with ClinicalTrials.gov, number NCT02464657. FINDINGS: Between Aug 7, 2015, and June 2, 2018, 44 patients were enrolled of whom 22 (50%) had adverse genetic risk by European Leukaemia Network classification. All patients were evaluable for safety and efficacy. At a median follow-up of 17·25 months (IQR 0·50-30·40), median event-free survival was not reached (95% CI 7·93-NR). Median relapse-free survival of responders was 18·54 months (95% CI 8·20-23·22). The median overall survival was 18·54 months (95% CI 10·81-28·81). Six patients had seven grade 3-4 immune-related adverse events with two cases of rash, two of colitis, and one each of transaminitis, pancreatitis, and cholecystitis. 19 (43%) of 44 patients achieved a response and proceeded to allogeneic stem cell transplantation, with grade 3-4 graft-versus-host disease observed in five (26%). No treatment related deaths were attributed to nivolumab. INTERPRETATION: Addition of nivolumab to induction chemotherapy with idarubicin and cytarabine is feasible in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome. Post-transplant severe graft-versus-host disease could be improved, and earlier initiation of checkpoint inhibitor therapy is warranted in future studies. FUNDING: The MD Anderson Cancer Center Support Grant CA016672, and the MD Anderson Cancer Center Leukaemia SPORE CA100632 from the National Cancer Institute, Bristol Myers Squibb.
引用
- Ravandi F, Assi R, Daver N, et al. Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study. Lancet Haematol. 2019. PMID: 31400961. doi:10.1016/S2352-3026(19)30114-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。